Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
This registry study enrolls people who have had a blood clot in a large blood vessel in their chest that is interfering with heart and lung blood flow. It enrolls people whose doctor has then decided to use a clot-dissolving drug in combination with a commercially-available device, called the EkoSonic® Endovascular System (EKOS). The purpose of this Registry is to understand how doctors are currently treating lung artery clots with clot-dissolving drugs and EKOS. Read More
Adults ages 18+.
Have a blood clot in one or both of the large blood vessels in your chest (lung arteries) that is interfering with blood flow through your heart
Your doctor has decided to use a clot-dissolving drug (thrombolytic drug) in combination with the EkoSonic® Endovascular System (EKOS).
The purpose of the study is to understand how Kovaltry is used by hemophilia A patients fo Read More
• Male patients diagnosed with moderate to severe hemophilia A
• Any age
• ≥ 50 exposure days (EDs) to any FVIII product
• Patients with or without history of inhibitors
• Patient with previous history of inhibitors, with at least 2 consecutive negative inhibitor tests and on standard prophylaxis therapy for at least 1 year prior to study en...